Study study type PathologyT1T0Patientssample sizesROB Results

mBC-Triple negative (TNBC) - 2nd Line (L2) breast cancer - triple negative mBC-Triple negative (TNBC) - 2nd Line (L2)

versus Standard of Care (SoC)
talazoparib
EMBRACA, 2018
  NCT01945775
RCTmBC-Triple negative (TNBC) - 2nd Line (L2)talazoparibchemotherapyPatients with HER2-negative locally advanced or metastatic breast cancer and a deleterious or suspected deleterious gBRCA1/2 mutation. Patients had received 3 or less previous cytotoxic regimens for advanced disease and previous treatment with a taxane, an anthracycline, or both (unless contraindicated).287 / 144NA
conclusif
  • inconclusive 15 % decrease in deaths (OS) (PE)
  • demonstrated 46 % decrease in progression or deaths (PFS) (PE)
  • demonstrated 4.0-fold increase in objective responses (ORR) (PE)